Amarin Corporation plc (AMRN) announced additional data from its MARINE and ANCHOR Phase 3 clinical trial results of Vascepa (icosapent ethyl) related to the effect of Vascepa on apolipoprotein C-III (Apo C-III).
The lipoprotein Apo C-III is thought to inhibit the clearance of triglycerides from the blood. People who do not produce Apo C-III have lower levels of triglycerides and lower instances of cardiovascular disease.
In Amarin's MARINE and ANCHOR trials, the 4 gram dose of Vascepa achieved reductions in Apo C-III levels of 25.1% (p<0.0001) and="" 19.2%=""><0.0001) compared="" to="" placebo,="">
Amarin previously announced the efficacy and safety results of its MARINE and ANCHOR trials, including achievement of the primary endpoints of these studies with respect to triglyceride reduction as well as the positive effect of Vascepa with respect to levels of apolipoprotein B (Apo B), non-high-density lipoprotein (non-HDL-C), total cholesterol (TC), and very low density lipoprotein cholesterol (VLDL-C).
Amarin noted that it plans to present additional data related to Vascepa's effect on Apo C-III at an upcoming scientific meeting.
For comments and feedback: editorial@rttnews.com